- Home
- DBRG vs CLDX Comparison
DBRG vs CLDX Comparison
Compare DBRG & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | CLDX |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | DBRG | CLDX |
|---|---|---|
| Price | $15.92 | $42.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $16.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 3.2M | 963.5K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ 557.14 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $93,959,000.00 | $12,743,000.00 |
| Revenue This Year | $373.39 | $111.39 |
| Revenue Next Year | $8.23 | $235.85 |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $8.94 | $20.37 |
| 52 Week High | $15.95 | $45.14 |
Technical Indicators
Market Signals| Indicator | DBRG | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.12 | 63.24 |
| Support Level | $15.33 | $28.51 |
| Resistance Level | $15.92 | N/A |
| Average True Range (ATR) | 0.04 | 1.71 |
| MACD | -0.00 | 0.24 |
| Stochastic Oscillator | 73.33 | 72.23 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.